focus -WSS

focus

author：entertainment 2025-09-29 21:28:00 - browse：754

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Boston's new lab space is opening empty

explore

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Top private equity targets in 2023: cardiology, clinical trials, lasers

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout Newsletter: CAR

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

Hollywood unions extend contract negotiations for actors

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Moonlake's readout produced a cash windfall. Risks remain

Why scientists need input from humanists on sensitive research

As demand for Covid shots wanes, Moderna seeks its next success

Medicare coverage of Wegovy, once blocked, now looks possible

After affirmative action ruling, medical educators look to 'holistic review'

Top private equity targets in 2023: cardiology, clinical trials, lasers

At least 13 dead in Texas as scorching temps continue

FDA advisers back CAR

knowledge

Unique patient identifier: Experts argue the benefits, pitfalls

WuXi out of biotech trade group, U.S. and China relations to blame

Amid AI frenzy, a top HHS official's quest to create safeguards

Why CTE doesn’t keep Americans from enjoying the Super Bowl

340B reform proposal comes out of Senate working group

The CDC's new social media misinformation war

knowledge

explore

hotspot

focus